HLX07
Sponsors
Henlix, Inc, Shanghai Henlius Biotech
Conditions
Advanced Hepatocellular CarcinomaCRCCutaneous Squamous Cell CarcinomaESCC or Esophageal Adenosquamous CarcinomaGastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)HLX07, nsqNSCLC, High EGFR ExpressionHead and Neck Squamous Cell CarcinomaNasopharyngeal Carcinoma by AJCC V8 Stage
Phase 1
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
CompletedNCT02648490
Start: 2016-09-30End: 2019-06-28Updated: 2019-07-30
HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors
NCT05360368
Start: 2023-03-30End: 2024-02-28Target: 24Updated: 2022-05-05
Phase 2
Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors
NCT04297995
Start: 2020-07-29End: 2025-06-30Target: 131Updated: 2023-08-08
A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression
NCT05215925
Start: 2023-02-01End: 2024-08-10Target: 60Updated: 2022-07-06
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC
NCT05221658
Start: 2022-08-25End: 2025-08-30Target: 60Updated: 2022-08-29
The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)
NCT05238363
Start: 2022-06-15End: 2024-07-15Target: 20Updated: 2022-06-21
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC
Not yet recruitingNCT05239650
Start: 2022-07-15End: 2026-10-15Target: 50Updated: 2022-05-03
HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer
NCT05246982
Start: 2022-03-23End: 2024-03-30Target: 40Updated: 2022-05-02
HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma
NCT05290220
Start: 2022-08-01End: 2024-12-15Target: 60Updated: 2022-05-03
A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer
NCT05354700
Start: 2023-03-29End: 2024-05-29Target: 20Updated: 2022-05-04
Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC
Active, not recruitingNCT05513573
Start: 2022-12-14End: 2026-09-30Target: 75Updated: 2024-06-17
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer
Not yet recruitingNCT07318883
Start: 2026-03-31End: 2031-01-31Target: 720Updated: 2026-01-06